Shamburg News · 8-K filed Nov 12, 2026, 4:17 PM EST

ProKidney Reports Third Quarter 2026 Financial Results and Business Highlights

PROK · PROKIDNEY CORP.

  • Earnings
  • Materiality: high

ProKidney Corp. reported financial results for the quarter ended September 30, 2026, including a net loss before noncontrolling interest of $51.8 million and research and development expenses of $40.8 million. Basic and diluted net loss per Class A share was $(0.17). The company reported cash, cash equivalents and marketable securities of $141.9 million as of September 30, 2026, and said it expects to complete PROACT 1 enrollment in Q1 2027 and report topline eGFR slope results in Q2 2027.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-458470.

Written from the filing by Shamburg Markets. Figures are as reported by the company.